Q1 2022 13F Holders as of 31 Mar 2022
-
Type / Class
-
Equity / Common Shares, no par value
-
Shares outstanding
-
31,523,534
-
Total 13F shares
-
1,312,831
-
Share change
-
-35,546
-
Total reported value
-
$6,741,558
-
Put/Call ratio
-
12%
-
Price per share
-
$5.14
-
Number of holders
-
14
-
Value change
-
-$232,854
-
Number of buys
-
6
-
Number of sells
-
8
Institutional Holders of ImmunoPrecise Antibodies Ltd. - Common Shares, no par value (IPA) as of Q1 2022
As of 31 Mar 2022 ImmunoPrecise Antibodies Ltd. - Common Shares, no par value (IPA) had 14 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 1,312,831 shares of stock of the company.
Largest 10 holders included INGALLS & SNYDER LLC, BANK OF MONTREAL /CAN/, Ikarian Capital, LLC, Federation des caisses Desjardins du Quebec, BANK OF AMERICA CORP /DE/, Gradient Capital Advisors, LLC, JPMORGAN CHASE & CO, GEODE CAPITAL MANAGEMENT, LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, and DIMENSIONAL FUND ADVISORS LP.
This table shows 15 institutional shareholders of the security as of 31 Mar 2022.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.